Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 LEXINGTON, Mass.–(BUSINESS WIRE)–Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its fourth quarter and full year 2022 financial results before the market opens on Thursday, March 30, 2023. … [Read more…]

DALLAS–(BUSINESS WIRE)–Healthmine, a leader in technology-enabled member engagement and reward solutions for health plans, has announced the promotion of Melissa Smith, Kimberly Swanson and Chris Dixon to key leadership roles. Melissa Smith, formerly the Executive Vice President of Consulting & Professional Services, will take the role of Chief Consulting Officer. For the past two years, … [Read more…]

Pragma Bio developed a first-of-its-kind-map of chemicals designed by nature, housed in humans, and linked to immune-related health outcomes SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Pragma Bio, the technology-enabled platform for drug discovery formerly known as VastBiome, announced it has raised an additional $10 million in equity to continue its development of proprietary methods in genomic sequencing, … [Read more…]

Cala continues to expand patient access to TAPS therapy and receives an upgraded clinical evidence assessment from ECRI SAN MATEO, Calif.–(BUSINESS WIRE)–#Neuromodulation–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study … [Read more…]

Results from a new survey of Hims & Hers’ employees has certified the company as a ‘great place to work’ for 2023 SAN FRANCISCO–(BUSINESS WIRE)–Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has been certified as a great place to work this month by the independent analyst … [Read more…]

WASHINGTON–(BUSINESS WIRE)–NeuroRPM Inc., a digital health company, has received FDA clearance for NeuroRPM, a breakthrough product that uses AI and Apple Watch to continuously and passively monitor bradykinesia, tremor, and dyskinesia, the cardinal symptoms of Parkinson’s disease. The product includes the most advanced and comprehensive monitoring capabilities for Parkinson’s disease available on a wearable device, … [Read more…]

LAUSANNE, Switzerland–(BUSINESS WIRE)–#spatialbiology—Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding. The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB) and existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. The funding includes a … [Read more…]

Recognized for Innovation, Automation and Using AI to Solve Industry-Specific Recruitment Challenges PHILADELPHIA–(BUSINESS WIRE)–#HRTech—Phenom, the global leader in Intelligent Talent Experience, today announced its high-volume hiring solution has earned the Business Intelligence Group’s 2023 Artificial Intelligence Excellence Award for AI innovation and applying its ability to solve organizations’ biggest recruitment challenges in a highly competitive … [Read more…]

BUDAPEST, Hungary–(BUSINESS WIRE)–Two leading pathology and diagnostics companies, 3DHISTECH of Hungary and Epredia, a member of PHC Group (headquartered in Japan), announce the opening of the Pathology Innovation Incubator in Budapest to develop methods and equipment for faster and more precise diagnosis of cancer and tumor lesions. The opening was announced today at an event … [Read more…]